#BEGIN_DRUGCARD DB05265

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Gastrom

# CAS_Registry_Number:
86408-72-2

# ChEBI_ID:
Not Available

# Chemical_Formula:
C20H28O5S

# Chemical_IUPAC_Name:
(1R,4aS,10aR)-1,4a-dimethyl-7-(propan-2-yl)-6-sulfo-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxylic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2007-11-18 11:22:56 -0700

# DPD_Drug_ID_Number:
Not Available

# Description:
Ecabet is a prescription eye drop for the treatment of dry eye syndrome. Ecabet represents a new class of molecules that increases the quantity and quality of mucin produced by conjunctival goblet cells and corneal epithelia. Mucin is a glycoprotein component of tear film that lubricates while retarding moisture loss from tear evaporation. Ecabet is currently marketed in Japan as an oral agent for treatment of gastric ulcers and gastritis.

# Dosage_Forms:
Not Available

# Drug_Category:
Anti-Infective Agents
Anti-Ulcer Agents
Anticarcinogenic Agents
Protease Inhibitors

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Ecabet

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C20H28O5S/c1-12(2)14-10-13-6-7-17-19(3,8-5-9-20(17,4)18(21)22)15(13)11-16(14)26(23,24)25/h10-12,17H,5-9H2,1-4H3,(H,21,22)(H,23,24,25)/t17-,19-,20-/m1/s1

# InChI_Key:
InChIKey=IWCWQNVIUXZOMJ-MISYRCLQSA-N

# Indication:
For the treatment of reflux oesophagitis and peptic ulcer disease.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
D07885

# LIMS_Drug_ID:
5266

# Mechanism_Of_Action:
Ecabet reduces the survival of H. pylori in the stomach and inhibits pepsin activity in the gastric juice of experimental animals. Here we have investigated the effects of ecabet on some of the factors involved in the dynamics of the mucosal barrier, i.e. pepsins and mucins. Pepsin, acid and Helicobacter pylori are major factors in the pathophysiology of peptic ulcer disease and reflux oesophagitis. Ecabet also acts as an inhibitor of H. pylori NADPH oxidase as well as urease. Inhibition of these enzymes prevents bacterial adhesion to gastric mucosa.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
380.498

# Molecular_Weight_Mono:
380.165744696

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA165958350

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
1.5

# Predicted_LogS:
-5

# Predicted_Water_Solubility:
4.26e-03 g/l

# Primary_Accession_No:
DB05265

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
65781

# PubChem_Substance_ID:
99443230

# RxList_Link:
Not Available

# Salts:
Ecabet sodium

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@@]12CCC3=CC(C(C)C)=C(C=C3[C@@]1(C)CCC[C@@]2(C)C(O)=O)S(O)(=O)=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:24:02 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Isoform 3:Cell membrane

# Drug_Target_1_Chromosome_Location:
1

# Drug_Target_1_Drug_References:
15458921	Kusumoto K, Kawahara T, Kuwano Y, Teshima-Kondo S, Morita K, Kishi K, Rokutan K: Ecabet sodium inhibits Helicobacter pylori lipopolysaccharide-induced activation of NADPH oxidase 1 or apoptosis of guinea pig gastric mucosal cells. Am J Physiol Gastrointest Liver Physiol. 2005 Feb;288(2):G300-7. Epub 2004 Sep 30.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
AF539796

# Drug_Target_1_GenBank_ID_Protein:
25573148

# Drug_Target_1_GeneCard_ID:
NOXO1

# Drug_Target_1_Gene_Name:
NOXO1

# Drug_Target_1_Gene_Sequence:
Not Available

# Drug_Target_1_General_Function:
Involved in enzyme binding

# Drug_Target_1_General_References:
12473664	Banfi B, Clark RA, Steger K, Krause KH: Two novel proteins activate superoxide generation by the NADPH oxidase NOX1. J Biol Chem. 2003 Feb 7;278(6):3510-3. Epub 2002 Dec 6.
12657628	Geiszt M, Lekstrom K, Witta J, Leto TL: Proteins homologous to p47phox and p67phox support superoxide production by NAD(P)H oxidase 1 in colon epithelial cells. J Biol Chem. 2003 May 30;278(22):20006-12. Epub 2003 Mar 25.
12716910	Takeya R, Ueno N, Kami K, Taura M, Kohjima M, Izaki T, Nunoi H, Sumimoto H: Novel human homologues of p47phox and p67phox participate in activation of superoxide-producing NADPH oxidases. J Biol Chem. 2003 Jul 4;278(27):25234-46. Epub 2003 Apr 25.
14617635	Cheng G, Lambeth JD: NOXO1, regulation of lipid binding, localization, and activation of Nox1 by the Phox homology (PX) domain. J Biol Chem. 2004 Feb 6;279(6):4737-42. Epub 2003 Nov 14.
15326186	Banfi B, Malgrange B, Knisz J, Steger K, Dubois-Dauphin M, Krause KH: NOX3, a superoxide-generating NADPH oxidase of the inner ear. J Biol Chem. 2004 Oct 29;279(44):46065-72. Epub 2004 Aug 23.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
15824103	Ueno N, Takeya R, Miyano K, Kikuchi H, Sumimoto H: The NADPH oxidase Nox3 constitutively produces superoxide in a p22phox-dependent manner: its regulation by oxidase organizers and activators. J Biol Chem. 2005 Jun 17;280(24):23328-39. Epub 2005 Apr 11.
15949904	Cheng G, Lambeth JD: Alternative mRNA splice forms of NOXO1: differential tissue expression and regulation of Nox1 and Nox3. Gene. 2005 Aug 15;356:118-26.
16329988	Park HS, Park D, Bae YS: Molecular interaction of NADPH oxidase 1 with betaPix and Nox Organizer 1. Biochem Biophys Res Commun. 2006 Jan 20;339(3):985-90.
17126813	Yamamoto A, Kami K, Takeya R, Sumimoto H: Interaction between the SH3 domains and C-terminal proline-rich region in NADPH oxidase organizer 1 (Noxo1). Biochem Biophys Res Commun. 2007 Jan 12;352(2):560-5. Epub 2006 Nov 20.

# Drug_Target_1_HGNC_ID:
GNC:19404

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
4190

# Drug_Target_1_Locus:
16p13.3

# Drug_Target_1_Molecular_Weight:
41252.3

# Drug_Target_1_Name:
NADPH oxidase organizer 1

# Drug_Target_1_Number_of_Residues:
376

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00018	SH3_1

# Drug_Target_1_Protein_Sequence:
>NADPH oxidase organizer 1
MAGPRYPVSVQGAALVQIKRLQTFAFSVRWSDGSDTFVRRSWDEFRQLKKTLKETFPVEA
GLLRRSDRVLPKLLGQASLDAPLLGRVGRTSRGLARLQLLETYSRRLLATAERVARSPTI
TGFFAPQPLDLEPALPPGSRVILPTPEEQPLSRAAGRLSIHSLEAQSLRCLQPFCTQDTR
DRPFQAQAQESLDVLLRHPSGWWLVENEDRQTAWFPAPYLEEAAPGQGREGGPSLGSSGP
QFCASRAYESSRADELSVPAGARVRVLETSDRGWWLCRYGDRAGLLPAVLLRPEGLGALL
SGTGFRGGDDPAGEARGFPEPSQATAPPPTVPTRPSPGAIQSRCCTVTRRALERRPRRQG
RPRGCVDSVPHPTTEQ

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Constitutively potentiates the superoxide-generating activity of NOX1 and NOX3 and is required for the biogenesis of otoconia/otolith, which are crystalline structures of the inner ear involved in the perception of gravity. Isoform 3 is more potent than isoform 1 in activating NOX3. Together with NOXA1, may also substitute to NCF1/p47phox and NCF2/p67phox in supporting the phagocyte NOX2/gp91phox superoxide-generating activity

# Drug_Target_1_SwissProt_ID:
Q8NFA2

# Drug_Target_1_SwissProt_Name:
NOXO1_HUMAN

# Drug_Target_1_Synonyms:
NADPH oxidase regulatory protein
Nox organizer 1
Nox-organizing protein 1
SH3 and PX domain-containing protein 5

# Drug_Target_1_Theoretical_pI:
10.23

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Cytoplasm

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
11472321	Adachi K, Ishihara S, Hashimoto T, Hirakawa K, Ishimura N, Niigaki M, Kaji T, Kawamura A, Sato H, Fujishiro H, Hattori S, Watanabe M, Kinoshita Y: Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen. Aliment Pharmacol Ther. 2001 Aug;15(8):1187-91.
11979876	Takahashi S, Tanaka A: [Ecabet sodium] Nippon Rinsho. 2002 Feb;60 Suppl 2:711-6.
12749277	Koizumi W, Tanabe S, Imaizumi H, Kida M, Ohida M, Koshida Y, Mitomi H, Hosaka Y, Nagaba S, Sasaki T, Higuchi K, Saigenji K: Inhibition of peptic ulcer relapse by ranitidine and ecabet independently of eradication of Helicobacter pylori: a prospective, controlled study versus ranitidine. Hepatogastroenterology. 2003 Mar-Apr;50(50):577-81.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
M36068

# Drug_Target_2_GenBank_ID_Protein:
149337

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
ureC

# Drug_Target_2_Gene_Sequence:
>1704 bp
ATGAGTAATATTTCACGCCAGGCCTATGCCGATATGTTCGGCCCCACCGTCGGCGACAAG
GTGCGCCTGGCAGATACCGAGCTGTGGATCGAGGTGGAGGACGATTTGACCACCTACGGG
GAAGAGGTCAAATTCGGCGGCGGCAAAGTGATCCGCGACGGCATGGGCCAGGGACAGATG
CTGGCCGCCGACTGTGTCGACCTGGTGCTCACCAACGCGTTGATCGTCGATCACTGGGGG
ATCGTTAAGGCCGATATCGGCGTGAAGGACGGCCGGATCTTCGCCATCGGCAAAGCCGGC
AACCCCGACATCCAGCCCAACGTCACCATCCCCATCGGCGCTGCGACGGAAGTGATCGCC
GCCGAAGGAAAAATTGTCACCGCCGGCGGGATCGATACCCATATTCACTGGATCTGTCCG
CAGCAGGCGGAAGAGGCGCTGGTCTCTGGCGTGACCACCATGGTCGGCGGCGGCACCGGC
CCGGCCGCGGGCACCCATGCCACCACCTGCACCCCGGGCCCGTGGTATATCTCACGCATG
CTGCAGGCGGCCGACAGCCTGCCGGTCAATATCGGCCTGCTGGGCAAGGGAAACGTTTCT
CAGCCGGATGCCCTGCGCGAGCAGGTGGCGGCAGGCGTTATTGGCCTGAAGATCCATGAG
GACTGGGGCGCCACCCCGGCGGCGATCGACTGTGCGTTAACCGTCGCCGATGAAATGGAC
ATCCAGGTCGCCCTGCACAGCGACACCCTGAATGAATCCGGTTTTGTGGAAGACACCCTC
GCCGCCATCGGCGGGCGCACCATCCACACCTTCCATACCGAAGGGGCCGGCGGCGGCCAT
GCGCCGGACATCATCACCGCCTGCGCCCACCCGAACATTTTGCCGTCGTCCACCAACCCA
ACGCTGCCCTACACCCTCAACACCATCGATGAACATCTCGATATGCTGATGGTCTGCCAC
CATCTGGACCCGGACATCGCCGAGGACGTGGCCTTTGCCGAGTCGCGCATTCGCCGGGAA
ACCATCGCTGCGGAAGACGTGCTGCACGATCTCGGCGCCTTCTCGCTCACCTCCTCCGAT
TCGCAGGCCATGGGCCGCGTCGGGGAAGTGATTCTCCGCACCTGGCAGGTGGCGCATCGC
ATGAAGGTGCAGCGCGGAGCGCTGGCGGAGGAGACCGGGGATAACGACAACTTCCGCGTG
AAGCGCTACATCGCCAAATACACCATCAACCCGGCGCTGACCCACGGCATCGCACACGAA
GTCGGATCCATTGAGGTGGGTAAGCTGGCTGACCTCGTGGTCTGGTCACCAGCCTTCTTC
GGCGTGAAACCGGCCACCGTGATCAAAGGCGGCATGATCGCCATCGCGCCGATGGGCGAT
ATCAATGCCTCTATTCCGACCCCGCAGCCGGTGCACTACCGCCCGATGTTTGGCGCGCTG
GGCAGCGCCCGCCATCACTGCCGCCTCACCTTCCTGTCGCAGGCGGCGGCAGCCAATGGC
GTTGCCGAGCGGCTGAACCTGCGCAGCGCGATCGCCGTGGTGAAAGGCTGCCGTACGGTG
CAGAAAGCCGACATGGTGCACAACAGTCTGCAGCCTAACATCACCGTCGACGCCCAGACC
TATGAGGTGCGGGTGGATGGCGAACTTATCACCAGCGAGCCGGCAGACGTTCTGCCGATG
GCGCAACGATATTTTCTGTTTTAA

# Drug_Target_2_General_Function:
Amino acid transport and metabolism

# Drug_Target_2_General_References:
10555581	Yamaguchi K, Cosper NJ, Stalhandske C, Scott RA, Pearson MA, Karplus PA, Hausinger RP: Characterization of metal-substituted Klebsiella aerogenes urease. J Biol Inorg Chem. 1999 Aug;4(4):468-77.
10913264	Pearson MA, Park IS, Schaller RA, Michel LO, Karplus PA, Hausinger RP: Kinetic and structural characterization of urease active site variants. Biochemistry. 2000 Jul 25;39(29):8575-84.
1624427	Lee MH, Mulrooney SB, Renner MJ, Markowicz Y, Hausinger RP: Klebsiella aerogenes urease gene cluster: sequence of ureD and demonstration that four accessory genes (ureD, ureE, ureF, and ureG) are involved in nickel metallocenter biosynthesis. J Bacteriol. 1992 Jul;174(13):4324-30.
2211515	Mulrooney SB, Hausinger RP: Sequence of the Klebsiella aerogenes urease genes and evidence for accessory proteins facilitating nickel incorporation. J Bacteriol. 1990 Oct;172(10):5837-43.
7754395	Jabri E, Carr MB, Hausinger RP, Karplus PA: The crystal structure of urease from Klebsiella aerogenes. Science. 1995 May 19;268(5213):998-1004.
8718850	Jabri E, Karplus PA: Structures of the Klebsiella aerogenes urease apoenzyme and two active-site mutants. Biochemistry. 1996 Aug 20;35(33):10616-26.
9558361	Pearson MA, Schaller RA, Michel LO, Karplus PA, Hausinger RP: Chemical rescue of Klebsiella aerogenes urease variants lacking the carbamylated-lysine nickel ligand. Biochemistry. 1998 Apr 28;37(17):6214-20.

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
370

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
60305

# Drug_Target_2_Name:
Urease alpha subunit

# Drug_Target_2_Number_of_Residues:
567

# Drug_Target_2_PDB_ID:
2KAU

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00449	Urease_alpha
PF01979	Amidohydro_1

# Drug_Target_2_Protein_Sequence:
>Urease alpha subunit
MSNISRQAYADMFGPTVGDKVRLADTELWIEVEDDLTTYGEEVKFGGGKVIRDGMGQGQM
LAADCVDLVLTNALIVDHWGIVKADIGVKDGRIFAIGKAGNPDIQPNVTIPIGAATEVIA
AEGKIVTAGGIDTHIHWICPQQAEEALVSGVTTMVGGGTGPAAGTHATTCTPGPWYISRM
LQAADSLPVNIGLLGKGNVSQPDALREQVAAGVIGLKIHEDWGATPAAIDCALTVADEMD
IQVALHSDTLNESGFVEDTLAAIGGRTIHTFHTEGAGGGHAPDIITACAHPNILPSSTNP
TLPYTLNTIDEHLDMLMVCHHLDPDIAEDVAFAESRIRRETIAAEDVLHDLGAFSLTSSD
SQAMGRVGEVILRTWQVAHRMKVQRGALAEETGDNDNFRVKRYIAKYTINPALTHGIAHE
VGSIEVGKLADLVVWSPAFFGVKPATVIKGGMIAIAPMGDINASIPTPQPVHYRPMFGAL
GSARHHCRLTFLSQAAAANGVAERLNLRSAIAVVKGCRTVQKADMVHNSLQPNITVDAQT
YEVRVDGELITSEPADVLPMAQRYFLF

# Drug_Target_2_Reaction:
urea + H2O = CO2 + 2 NH3

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Not Available

# Drug_Target_2_SwissProt_ID:
P18314

# Drug_Target_2_SwissProt_Name:
URE1_KLEAE

# Drug_Target_2_Synonyms:
EC 3.5.1.5
Urea amidohydrolase alpha subunit

# Drug_Target_2_Theoretical_pI:
5.03

# Drug_Target_2_Transmembrane_Regions:
None

#END_DRUGCARD DB05265
